Current Opinion in Pulmonary Medicine最新文献

Bronchiectasis in immunodeficiency. 免疫缺陷所致的支气管扩张。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-10-01 DOI: 10.1097/MCP.0000000000001310

Jordon L Jaggers, James M Fernandez

{"title":"Bronchiectasis in immunodeficiency.","authors":"Jordon L Jaggers, James M Fernandez","doi":"10.1097/MCP.0000000000001310","DOIUrl":"10.1097/MCP.0000000000001310","url":null,"abstract":"Purpose of review: As the field of bronchiectasis continues to advance, so does the recognition of undiagnosed immunodeficiency as a potential contributor. This review aims to highlight what is currently known about bronchiectasis in immunodeficiency as well as explore future therapeutics and needs.Recent findings: Guidelines emphasize the need for evaluation for underlying immunodeficiency in patients with known bronchiectasis. Despite this known association, evaluation continues to be variable in clinical practice resulting in potentially missed therapeutic options, such as immunoglobulin replacement therapy in the setting of immunodeficiency. While the mainstay treatment for those with bronchiectasis and immunodeficiency continues to be immunoglobulin replacement therapy and prophylactic antibiotics, the future is hopeful with more directed therapy for the underlying pathophysiology of bronchiectasis with targeted agents such as brensocatib.Summary: This review highlights the need for ongoing research to improve detection of bronchiectasis in immunodeficiency and include patients with immunodeficiency and bronchiectasis in trial designs for therapeutics in bronchiectasis.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"582-586"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Latest updates in quality of life and psychological impact of sarcoidosis. 结节病的生活质量和心理影响的最新进展。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-10-01 DOI: 10.1097/MCP.0000000000001316

Dominique Israël-Biet, Dov Taïeb, Jean Pastré

引用次数: 0

Management of restless legs syndrome when gabapentinoids fail: intravenous iron and opioids. 加巴喷丁类药物失效时不宁腿综合征的管理：静脉注射铁和阿片类药物。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-09-07 DOI: 10.1097/MCP.0000000000001308

Lauren T Berry, John W Winkelman

{"title":"Management of restless legs syndrome when gabapentinoids fail: intravenous iron and opioids.","authors":"Lauren T Berry, John W Winkelman","doi":"10.1097/MCP.0000000000001308","DOIUrl":"10.1097/MCP.0000000000001308","url":null,"abstract":"Purpose of review: This review addresses the management of restless legs syndrome (RLS) when first-line gabapentinoid therapy fails or is not tolerated. We provide an update on treatment options in the context of the 2025 American Academy of Sleep Medicine (AASM) guideline, which substantially reorganized the treatment hierarchy for RLS.Recent findings: The 2025 AASM guideline elevated all gabapentinoids and intravenous ferric carboxymaltose to strong first-line recommendations while repositioning dopamine agonists away from routine long-term use because of augmentation and impulse control disorder risk. Emerging data suggest the ferritin and transferrin saturation thresholds guiding iron repletion may be more permissive than previously appreciated, extending benefit to a broader range of patients. Long-term registry data now extending to 5 years show that low-dose opioids remain effective and largely stable over time in RLS, a pattern distinct from the dose escalation seen in chronic pain, and a mechanistic rodent model has identified a dopaminergic pathway distinct from nociceptive pain pathways that may underlie this difference. Device-based tonic motor activation has emerged as a well tolerated, conditionally recommended nonpharmacologic option, including as an adjunct that may enable opioid dose reduction.Summary: The management of gabapentinoid-refractory RLS is no longer a single default step toward dopamine agonist therapy. Clinicians now have a broader set of well supported options, including expanded intravenous iron candidacy, low-dose opioids, and device-based therapy, that should be selected through a shared decision-making process weighing the durability and risks specific to each patient.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"525-529"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eosinophils in bronchiectasis. 支气管扩张中的嗜酸性粒细胞。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-10-01 DOI: 10.1097/MCP.0000000000001315

Megan Trieu, Praveen Akuthota, Jeffrey Barry

{"title":"Eosinophils in bronchiectasis.","authors":"Megan Trieu, Praveen Akuthota, Jeffrey Barry","doi":"10.1097/MCP.0000000000001315","DOIUrl":"10.1097/MCP.0000000000001315","url":null,"abstract":"Purpose of review: Bronchiectasis has traditionally been viewed as a predominantly neutrophil-driven airway disease. Recognition of eosinophilic inflammation in a substantial subset of patients has challenged this paradigm. This review summarizes emerging evidence regarding its pathogenesis, clinical significance, and therapeutic implications.Recent findings: Eosinophilic bronchiectasis is identified using blood or sputum eosinophilia, although optimal biomarkers and thresholds are unclear. Eosinophilic inflammation occurs in bronchiectasis and overlapping disease states characterized by type 2 immune activation, including asthma, allergic bronchopulmonary aspergillosis, and cystic fibrosis, complicating diagnosis but potentially informing disease severity, prognosis, and treatment options. Evidence for targeted therapies is limited to largely observational data. Patients with elevated eosinophil counts may derive greater benefit from inhaled corticosteroids. Early studies of biologics appear promising, particularly in patients with coexisting ABPA or asthma, although their benefit in eosinophilic bronchiectasis independent of these conditions remains uncertain.Summary: Eosinophilic bronchiectasis represents a distinct inflammatory endotype that may enable a more personalized approach to disease management. Future studies should identify clinically relevant biomarkers to standardize its definition, clarify its relationship with overlapping type 2 airway diseases, and guide the use of inhaled corticosteroids and biologics.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"568-574"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reflux in bronchiectasis: current evidence and clinical implications. 支气管扩张的反流：目前的证据和临床意义

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-09-07 DOI: 10.1097/MCP.0000000000001309

Robert C Flowers, Shreya Chablaney, Ashwin Basavaraj

{"title":"Reflux in bronchiectasis: current evidence and clinical implications.","authors":"Robert C Flowers, Shreya Chablaney, Ashwin Basavaraj","doi":"10.1097/MCP.0000000000001309","DOIUrl":"10.1097/MCP.0000000000001309","url":null,"abstract":"Purpose of review: To describe the relationship between reflux and bronchiectasis and to appraise recent literature on reflux characterization, clinical outcomes, and management strategies in patients with bronchiectasis.Recent findings: Reflux is common in bronchiectasis and has been linked to worse respiratory symptoms and quality of life, more exacerbations and healthcare use, lower lung function, and higher mortality. These associations are seen across several cohorts, but nearly all data are observational, use variable reflux definitions, and cannot determine whether reflux contributes to bronchiectasis progression or simply identifies patients with more severe disease. Proposed pathways include microaspiration-related airway injury, reflex-mediated cough amplification, and microbial dysbiosis. No randomized bronchiectasis-specific trial has shown improved respiratory outcomes with reflux-directed therapy, and acid suppression alone is unlikely to address nonacid reflux, microaspiration, cough-reflex pathways, or airway dysbiosis.Summary: In bronchiectasis, reflux should be separated into clinically relevant phenotypes, including typical gastroesophageal reflux disease, proximal or nonacid reflux, laryngopharyngeal symptoms, dysphagia, and aspiration. Management should be guided by the suspected reflux or aspiration pattern because acid suppression alone may not address airway-relevant reflux. Future studies should pair objective reflux and swallowing measures with bronchiectasis-specific outcomes.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"575-581"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis. 囊性纤维化和支气管扩张的医疗问题和肺结局。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-10-01 DOI: 10.1097/MCP.0000000000001314

George Doumat, Manya Iyer, Raksha Jain

{"title":"Medical issues and pulmonary outcomes in cystic fibrosis and bronchiectasis.","authors":"George Doumat, Manya Iyer, Raksha Jain","doi":"10.1097/MCP.0000000000001314","DOIUrl":"10.1097/MCP.0000000000001314","url":null,"abstract":"Purpose of review: Bronchiectasis from cystic fibrosis and noncystic fibrosis causes include a spectrum of chronic suppurative airway conditions that share key pathophysiologic mechanisms but differ substantially in genetic basis, epidemiology, and clinical course. Recent therapeutic advances, particularly highly effective CFTR modulators in cystic fibrosis and emerging anti-inflammatory therapies in bronchiectasis, have reshaped disease management and prompted re-evaluation of treatment paradigms, outcome measures, and approaches to long-term monitoring.Recent findings: In cystic fibrosis, highly effective CFTR modulator therapy, including elexacaftor/tezacaftor/ivacaftor and the recently approved once daily vanzacaftor/tezacaftor/deutivacaftor, has produced sustained increase in lung function, reduced frequency of pulmonary exacerbations, and improved quality of life, while highlighting the limitations of FEV 1 as a sole future marker of treatment response. In noncystic fibrosis bronchiectasis, the phase 3 ASPEN trial demonstrated that brensocatib, a dipeptidyl peptidase-1 inhibitor, significantly reduces exacerbation frequency and slows lung function decline at the higher dose, representing a potential disease-modifying therapy. Emerging evidence also underscores the prognostic importance of comorbidities and disease modifiers, including Pseudomonas aeruginosa and gastroesophageal reflux disease.Summary: Management of all forms of bronchiectasis is increasingly shifting toward individualized, endotype-directed care. Integration of disease-modifying therapies, systematic assessment of comorbidities, validated severity stratification tools, and patient-reported outcomes will be essential to optimizing long-term clinical outcomes and advancing precision medicine approaches across this heterogeneous disease spectrum.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"559-567"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Parsonage-turner syndrome: a pulmonologist's guide to the forgotten diaphragm. 帕森纳-特纳综合症：肺科医生对被遗忘的横膈膜的指南。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-10-01 DOI: 10.1097/MCP.0000000000001305

Sara Hanif Mirza

{"title":"Parsonage-turner syndrome: a pulmonologist's guide to the forgotten diaphragm.","authors":"Sara Hanif Mirza","doi":"10.1097/MCP.0000000000001305","DOIUrl":"10.1097/MCP.0000000000001305","url":null,"abstract":"Purpose of review: Parsonage-Turner syndrome (PTS), or neuralgic amyotrophy, is framed as a shoulder disorder owned by neurology, and that framing has cost pulmonologists patients. Roughly 1 in 13 develops phrenic neuropathy, and many patients referred for unexplained dyspnea, orthopnea, or rapid eye movement (REM)-predominant sleep-disordered breathing have an undiagnosed, treatable inflammatory neuropathy. This review reframes PTS for pulmonologists.Recent findings: Three developments have reshaped practice. High-resolution neuromuscular ultrasound and MR neurography now identify the hourglass constrictions and fascicular entwinement of PTS at the bedside, including in the phrenic nerve. COVID-19 infection and SARS-CoV-2 vaccination produced a global cluster, expanding the phenotype toward bilateral and respiratory-predominant disease. Large Dutch cohort data have replaced anecdote with structure: roughly 60% of patients with phrenic involvement recover meaningfully within 2 years, while the remainder respond best to early noninvasive ventilation and, in refractory cases, diaphragmatic plication.Summary: Every pulmonologist evaluating unexplained dyspnea, disproportionate orthopnea, or REM-predominant hypopneas should ask one question: was there severe shoulder or neck pain in the weeks before the breathing changed? If yes, screen with upright and supine spirometry and diaphragm ultrasound. The diagnosis is reachable in a single visit, the immunomodulation window is short, and the cost of missing it is years of avoidable disability.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"536-542"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The promise of quantitative approaches to computed tomography imaging in pulmonary sarcoidosis. 肺结节病计算机断层成像定量方法的前景。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-08-24 DOI: 10.1097/MCP.0000000000001301

Wren L Lippitt, Nichole E Carlson

{"title":"The promise of quantitative approaches to computed tomography imaging in pulmonary sarcoidosis.","authors":"Wren L Lippitt, Nichole E Carlson","doi":"10.1097/MCP.0000000000001301","DOIUrl":"10.1097/MCP.0000000000001301","url":null,"abstract":"Purpose of review: Pulmonary sarcoidosis is characterized by marked radiologic heterogeneity and limited reproducibility of visual high-resolution computed tomography (HRCT) assessment, which together restrict standardization, phenotyping, and prognostication. This review examines the potential that quantitative and artificial intelligence-based approaches offer in solving these challenges. It then offers key insights into the solutions needed to fully realize the value of HRCT imaging in pulmonary sarcoidosis.Recent findings: Early quantitative and artificial intelligence-driven studies demonstrate that HRCT images can be transformed into objective, reproducible numerical representations that capture disease patterning beyond conventional visual interpretation. These approaches show promise for clinically relevant and standardized assessment of pulmonary involvement. However, in sarcoidosis, existing work remains largely preliminary and limited by small sample sizes, single center designs, technical heterogeneity, and unreliable ground truth imaging labels. Recent studies also highlight opportunities for alternative quantitative strategies that may be better suited to the data constraints of rare diseases.Summary: Quantitative HRCT analysis offers a compelling framework for advancing imaging-based assessment in pulmonary sarcoidosis, but meaningful progress will require large multicenter cohorts and more objective nonimaging outcomes that move beyond subjective visual assessment. Quantitative imaging may then help reposition HRCT as a reproducible biomarker platform for research and clinical care.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"587-592"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148812408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disparities in sleep-disordered breathing: epidemiology, mechanisms, and pathways toward equity- a narrative review. 睡眠呼吸障碍的差异：流行病学、机制和通向公平的途径——叙述性回顾。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-09-01 DOI: 10.1097/MCP.0000000000001304

Adrianna Elashker, Justin A Fiala

{"title":"Disparities in sleep-disordered breathing: epidemiology, mechanisms, and pathways toward equity- a narrative review.","authors":"Adrianna Elashker, Justin A Fiala","doi":"10.1097/MCP.0000000000001304","DOIUrl":"10.1097/MCP.0000000000001304","url":null,"abstract":"Purpose of review: Sleep-disordered breathing (SDB), encompassing obstructive sleep apnea (OSA) and related conditions, affects tens of millions of individuals in the United States and is associated with substantial cardiovascular, metabolic, and neurocognitive morbidity. However, the burden of SDB is not equally distributed across racial, ethnic, and socioeconomic groups, with significant disparities in referral, diagnosis, and treatment of these conditions within traditionally underserved populations.Recent findings: Racial and ethnic minority populations, most notably Black, Hispanic/Latinx, and Asian Americans, experience higher prevalence of SDB, greater severity at diagnosis, and lower rates of effective treatment compared with non-Hispanic White populations. Societal determinants including neighborhood disadvantage, occupational exposures, structural racism, and variable/suboptimal access to diagnosis and treatment propagate these inequities resulting in disparities in treatment outcomes, as exemplified by lower adherence rates to continuous positive airway pressure (CPAP) therapy in minoritized groups, even after adjustment for clinical confounders.Summary: Addressing disparities in SDB requires multilevel interventions spanning individual clinical care, health system redesign, and policy reform. Culturally adapted diagnostic pathways, community-engaged implementation strategies, and expanded insurance coverage for sleep studies and positive airway pressure therapy represent actionable near-term priorities.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"530-535"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary hypertension related to sleep-disordered breathing. 与睡眠呼吸障碍有关的肺动脉高压。

IF 2.7 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2026-11-01 Epub Date: 2026-09-07 DOI: 10.1097/MCP.0000000000001307

Margeaux LaCavera, Aleezay Asghar, Joseph Ballard, Mohit Bandla, Dustin R Fraidenburg

{"title":"Pulmonary hypertension related to sleep-disordered breathing.","authors":"Margeaux LaCavera, Aleezay Asghar, Joseph Ballard, Mohit Bandla, Dustin R Fraidenburg","doi":"10.1097/MCP.0000000000001307","DOIUrl":"10.1097/MCP.0000000000001307","url":null,"abstract":"Purpose of review: Sleep-disordered breathing (SDB) is an increasingly recognized contributor to WHO Group 3 pulmonary hypertension (PH). This review examines the epidemiology and pathophysiology linking SDB to PH, evaluates the evidence base for sleep-directed therapies in modifying pulmonary hemodynamics, and highlights emerging treatment modalities that may be able to alter disease course.Recent findings: The mechanisms underlying SDB-related PH are multifactorial, including recurrent nocturnal hypoxemia, altered intrathoracic pressures, and obesity-driven metabolic and inflammatory dysregulation. Positive airway pressure therapy remains the cornerstone of treatment of SDB-related PH, though mandibular advancement devices and hypoglossal nerve stimulation offer viable alternatives. Hypoxic burden, rather than apnea-hypopnea index alone, is increasingly recognized as a better predictor for cardiovascular and pulmonary vascular outcomes in SDB. Long-term oxygen therapy provides hemodynamic benefit in patients with resting hypoxemia, though evidence is limited in those with isolated nocturnal desaturation.Summary: SDB is an underdiagnosed and clinically important contributor to PH. Early identification and treatment, particularly with positive airway pressure therapy when indicated, can meaningfully reduce pulmonary arterial pressures. Future research should prioritize prospective trials examining the direct impact of glucagon-like peptide-1 receptor agonists and bariatric surgery on pulmonary hemodynamics and standardize the use of hypoxic burden as a clinical endpoint.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"551-558"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148910947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0